InvestorsObserver
Sign Up Login

CBAY Cymabay Therapeutics

$2.86 $-0.08 (-2.72%)
Add to Watchlist Compare
Overall

CBAY Stock Analysis Overview

What this means: InvestorsObserver gives Cymabay Therapeutics (CBAY) an overall rank of 30, which is below average. Cymabay Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 30 means that 70% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

CBAY Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

CBAY Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

CBAY Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

CBAY Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

CBAY Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

CBAY Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

CBAY Stock Analysis Overview

What this means: InvestorsObserver gives Cymabay Therapeutics (CBAY) an overall rank of 30, which is below average. Cymabay Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 30 means that 70% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full CBAY report

CBAY Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

CBAY Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

CBAY Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

CBAY Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

CBAY Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

CBAY Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Cymabay Therapeutics (CBAY) Analyst Forecast

CBAY Price, Volume, Earnings, and Dividend Date

  • Last Price $2.86
  • Previous Close $2.94
  • Change $-0.08
  • Open $3.00
  • Volume 440,654
  • Avg. Volume (100-day) 488,018
  • Market Cap 242,153,251
  • Days Range 2.84 - 3.03
  • 52-week Range 2.76 - 6.56
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 02/08/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.343
  • PEG Ratio —

Cymabay Therapeutics (CBAY) Company Description

CymaBay Therapeutics Inc is a part of the healthcare sector based in the United States. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.

Cymabay Therapeutics (CBAY) Stock Chart

View Interactive CBAY chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Sierra Oncology Inc (SRRA) (SRRA) $28.64
Genfit S.A. ADR (GNFT) (GNFT) $4.07
Fennec Pharmaceuticals Inc (FENC) (FENC) $4.64
Xenon Pharmaceuticals Inc (XENE) (XENE) $26.48
Catalyst Pharm Inc (CPRX) (CPRX) $5.53
Viridian Therapeutics Inc (VRDN) (VRDN) $18.17
Opiant Pharmaceuticals Inc (OPNT) (OPNT) $27.00
Tricida Inc (TCDA) (TCDA) $9.83
Bellus Health Inc (BLU) (BLU) $5.90
Vertex Pharmaceutic (VRTX) (VRTX) $226.58